Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. It focuses on the development of antivirals for HIV infection and chronic hepatitis C; and antibacterials for serious hospital-based bacterial infections. The company’s lead drug candidates are elvucitabine, an antiviral in phase II clinical trials for the treatment of HIV infection; and ACH-806 (also known as GS 9132), a phase I clinical trial product for the treatment of chronic hepatitis C. Achillion is also evaluating ACH-702, which is in late-stage preclinical studies for the treatment of serious hospital-based bacterial infections. The company has research collaboration and license agreement with Gilead Sciences, Inc. to develop and commercialize compounds for the treatment of chronic HCV, as well as a research collaboration agreement with UMBC and Howard Hughes Medical Center. Achillion was founded in 1998 and is headquartered in New Haven, Connecticut.